Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 73-84 of 214 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 73-84 of 214 studies
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of ivacaftor in babies 12-24 month old who have a CFTR gating mutation , protocol number Vertex VX15-770-124This study evaluated the safety of ivacaftor (Kalydeco®) as well as how the body processes the drug in babies who have at least one copy of a CFTR gating mutation.
-
Age:
12 Months to 24 Months
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
24 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 2 study of PTI-428 drug in people with CF ages 18 and older who have two copies of the F508del CFTR mutation , protocol number Proteostasis PTI-428-06This study evaluated the safety and tolerability of the drug PTI-428. This study was for people with CF ages 18 and older who have two copies of the F508del CFTR mutation and were already taking tezacaftor/ivacaftor (Symdeko®). A key goal of the study was to determine if PTI-428 could increase the amount of CFTR protein produced in people who were already taking tezacaftor/ivacaftor (Symdeko®).
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
74 days
-
-
Restore CFTR ProteinCompleted with Results
Study of VX-445 plus ivacaftor and tezacaftor in people with CF who have two copies of the F508del CFTR mutation , protocol number Vertex VX17-445-103This study evaluated the effectiveness and safety of the CFTR modulator drug VX-445 (elexacaftor) in combination with ivacaftor and tezacaftor. This triple combination is known as Trikafta™. This study was for people with CF ages 12 and older who have two copies of the F508del CFTR mutation and were already taking tezacaftor plus ivacaftor.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
7
-
Length of Participation:
10 weeks
-
-
Restore CFTR ProteinCompleted with Results
Study of effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in people with CF who have one copy of the F508del CFTR mutation , protocol number Vertex VX17-445-102This study evaluated the effectiveness and safety of the CFTR modulator drug VX-445 (elexacaftor) in combination with tezacaftor and ivacaftor (ELX/TEZ/IVA). This triple combination drug is known as Trikafta™. This study was for people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
32 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of VX-659 triple combination drug in people with CF ages 12 years and older who have two copies of the F508del mutation , protocol number VX17-659-103This study evaluated the safety and effectiveness of the drug VX-659 in combination with tezacaftor and ivacaftor in people with cystic fibrosis ages 12 and older with two copies of the F508del CFTR mutation.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
7
-
Length of Participation:
10 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of VX-659 triple combination drug in people with CF 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation , protocol number VX17-659-102This study evaluated the safety and effectiveness of the drug VX-659 in combination with tezacaftor and ivacaftor in people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
32 weeks
-
-
Restore CFTR ProteinCompleted with Results
A study to evaluate tezacaftor/ivacaftor in adults with cystic fibrosis and two copies of the F508del mutation , protocol number Vertex VX16-661-114This study evaluated the safety, effectiveness, and tolerability of the drug tezacaftor/ivacaftor (Symdeko®). This study was for people with CF ages 12 and older with two copies of the F508del CFTR mutation who had been taken off lumacaftor/ivacaftor (Orkambi®) due to respiratory side effects.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
25 to 90%
-
Number of Visits:
5
-
Length of Participation:
84 days
-
-
Restore CFTR ProteinCompleted with Results
Phase 2 study of VX-659 combination drug in adults with cystic fibrosis , protocol number Vertex VX16-659-101This study evaluated the safety, tolerability and effectiveness of the drug VX-659 in combination with tezacaftor/ivacaftor (Symdeko®) in people who either have two copies of the F508del CFTR mutation or have one copy of F508del and one copy of a minimal function CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
6
-
Length of Participation:
8 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 1/2 study of VX-445 combination drug in healthy adults and then in people with cystic fibrosis , protocol number VX-445-001This study evaluated the safety, tolerability and effectiveness of the drug VX-445 in combination with tezacaftor/ivacaftor (Symdeko®) in people who either have two copies of the F508del CFTR mutation or have one copy of F508del and one copy of a minimal function CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
6
-
Length of Participation:
12 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 2a study of Galapagos GLPG2222 in adults with CF , protocol number GLPG2222-CL-202This study evaluated the safety and effectiveness of the CFTR modulator GLPG2222. This study was for people with CF who have two copies of the F508del mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
5
-
Length of Participation:
10 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of Vertex 661 and ivacaftor in people with CF who have one copy of the F508del-CFTR mutation and a second CFTR mutation predicted to have residual function , protocol number Vertex VX-661-108This study evaluated the safety and effectiveness of the drug VX-661 in combination with ivacaftor (Kalydeco®) versus ivacaftor alone versus placebo. This study was for people with CF who have one copy of the F508del CFTR mutation and a CFTR mutation associated with residual CFTR function.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
12
-
Length of Participation:
33 weeks
-
-
Restore CFTR ProteinCompleted with Results
VX 809 and ivacaftor in people with CF who are aged 12 years and older and have two copies of the F508del-CFTR mutation (105) , protocol number Vertex VX-809-105This was an open-label follow-on study that evaluated the safety and efficacy of lumacaftor in combination with ivacaftor (Orkambi®) in people with CF, 12 years and older and who have two copies of the F508del genetic mutation.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
7
-
Length of Participation:
96 weeks
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More